Le Lézard
Classified in: Health
Subjects: CHI, RCL, PSF

Advisory - Several children's strawberry-flavoured acetaminophen syrups recalled because of defective child-resistant safety caps on the bottles


OTTAWA, Nov. 14, 2018 /CNW/ -

Biomedic Acetaminophen (160 mg/5 mL) children's syrup, strawberry flavour (lot B0504-A) (CNW Group/Health Canada)

Issue
Laboratoire Riva Inc. and Laboratoires Trianon Inc. are voluntarily recalling several over-the-counter children's strawberry-flavoured acetaminophen syrups labeled as Biomedic, Option+, or Laboratoires Trianon Inc. The products, which are used for pain and fever relief, are being recalled because the child-resistant safety cap may be defective.

A defective cap could allow a child to accidentally ingest the product, which would pose a significant health concern. Accidental ingestion can result in acetaminophen overdose and serious health consequences, including liver damage in extreme cases. Early signs of overdose include nausea, vomiting, lethargy and sweating. Liver damage may result in liver failure or death. Abdominal pain may be the first sign of liver damage and may not be apparent for 24 to 48 hours.

This issue is related to product packaging and not the safety or effectiveness of the drug in the bottles. The products were distributed at major pharmacies across Canada.

Who is affected

Affected products

 

Description

Company

DIN

Lot

Expiry

Units Distributed

Biomedic Acetaminophen

(160 mg/5 mL) children's syrup, strawberry flavour 

Laboratoire Riva Inc.

02226871

B0504-A

21-MA

3,360

Option+ Acetaminophen oral solution USP

(160 mg/5 mL) children's syrup, strawberry flavour 

Laboratoire Riva Inc.

02226871

B0504-C

2021-MA

2,364

Laboratoires Trianon Inc. Acetaminophen Oral solution USP

(160 mg/5 mL) children's syrup, strawberry flavour

Laboratoires Trianon Inc.

01958836

B0504-B

21-MA

998

B0504-E

2021-MA

2,264

 

What consumers should do

What Health Canada is doing
Health Canada is monitoring the recalls. Should additional safety concerns be identified related to this issue, Health Canada will take appropriate action and inform Canadians as necessary.

Stay connected with Health Canada and receive the latest advisories and product recalls.

Également disponible en français

 

Option+ Acetaminophen (160 mg/5 mL) children's syrup, strawberry flavour (lot B0504-C) (CNW Group/Health Canada)

Laboratoires Trianon Inc. Acetaminophen (160 mg/5 mL) children's syrup, strawberry flavour (lot B0504-E) (CNW Group/Health Canada)

Laboratoires Trianon Inc. Acetaminophen (160 mg/5 mL) children's syrup, strawberry flavour (lot B0504-B) (CNW Group/Health Canada)

SOURCE Health Canada


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: